title: Invasive Cryptococcosis and adalimumab treatment.
authors.forename: Juan P
authors.initials: JP
authors.lastname: Horcajada
authors.forename: Jose L
authors.initials: JL
authors.lastname: Peña
authors.forename: Víctor M
authors.initials: VM
authors.lastname: Martínez-Taboada
authors.forename: Trinitario
authors.initials: T
authors.lastname: Pina
authors.forename: Isabel
authors.initials: I
authors.lastname: Belaustegui
authors.forename: María Eliecer
authors.initials: ME
authors.lastname: Cano
authors.forename: Daniel
authors.initials: D
authors.lastname: García-Palomo
authors.forename: M Carmen
authors.initials: MC
authors.lastname: Fariñas
mesh_terms: D000068879:Adalimumab; D000368:Aged; D000671:Amputation, Surgical; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D003453:Cryptococcosis / Q000276:immunology* / Q000473:pathology / Q000601:surgery; D005260:Female; D005385:Fingers / Q000382:microbiology* / Q000473:pathology; D006801:Humans; D016867:Immunocompromised Host; D009894:Opportunistic Infections / Q000473:pathology / Q000601:surgery; D013717:Tenosynovitis / Q000382:microbiology* / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000068879:Adalimumab